Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes cancer medicines, most notably cabozantinib, sold in the U.S. as CABOMETYX for kidney and liver cancers and as COMETRIQ for a rare thyroid cancer. Founded in 1994 by scientists from Yale and UC Berkeley who began by studying fruit flies and zebrafish to find drug targets, the company is now a fully integrated oncology drugmaker. Its name comes from the Greek word for "evolution," a nod to how the firm itself evolved from a genomics startup into a commercial drug company.
Exelixis stockholders approve 2017 Equity Incentive Plan amendment and restatement at 2026 Annual Meeting
All 11 director nominees were elected to serve until the 2027 annual meeting.
Show detailsHide details
On May 26, 2026, Exelixis held its 2026 Annual Meeting via live webcast.
Stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan, effective immediately upon approval.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending January 1, 2027.
Stockholders approved the Say on Pay proposal for named executive officer compensation.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Exelixis reports Q4 2025 revenue of $598.7M and full-year 2025 revenue of $2.320B
Total revenues for Q4 2025 were $598.7 million, up from $566.8 million in Q4 2024; full-year 2025 revenues were $2.320 billion, up from $2.169 billion in 2024.
Show detailsHide details
Net product revenues were $546.6 million in Q4 2025 and $2.123 billion for full-year 2025, driven by increased sales volume.
GAAP diluted EPS was $0.88 for Q4 2025 and $2.78 for full-year 2025, compared to $0.48 and $1.76 in the prior-year periods.
The FDA accepted the NDA for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, with a PDUFA date of December 3, 2026.
2026 financial guidance: total revenues of $2.525-$2.625 billion and net product revenues of $2.325-$2.425 billion, excluding any zanzalintinib launch revenues.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Exelixis General Counsel Jeffrey Hessekiel resigns; Brenda Hefti promoted to succeed him
Jeffrey Hessekiel, Executive Vice President and General Counsel, notified Exelixis of his resignation on November 4, 2025, effective November 7, 2025.
Show detailsHide details
Hessekiel's departure was not due to any disagreement with the company.
Brenda Hefti, Senior Vice President of IP & Licensing, will be promoted to General Counsel effective November 7, 2025, reporting to CEO Michael Morrissey.
Hefti joined Exelixis in 2013 as corporate counsel, became Head of IP in 2014, and has been SVP of IP & Licensing since 2020.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 8.01 Other Events
Exelixis appoints Dana T. Aftab as EVP of R&D; Amy C. Peterson departs as CMO
On August 29, 2025, Exelixis' Board appointed Dana T. Aftab, Ph.D., as Executive Vice President, Research and Development, effective immediately.
Show detailsHide details
Dr. Aftab previously served as Executive Vice President, Discovery and Translational Research and Chief Scientific Officer.
Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, effective August 29, 2025.
Dr. Peterson is entitled to payments under the Company's Change in Control and Severance Benefit Plan and applicable law.
Details of Dr. Aftab's compensation and background are incorporated by reference from Exelixis' April 16, 2025 proxy statement.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements